Dosimetric and clinical predictors of toxicity following combined chemotherapy and moderately hypofractionated rotational radiotherapy of locally advanced pancreatic adenocarcinoma

被引:37
作者
Cattaneo, Giovanni M. [1 ]
Passoni, Paolo [2 ]
Longobardi, Barbara [1 ]
Slim, Najla [2 ]
Reni, Michele [3 ]
Cereda, Stefano [3 ]
di Muzio, Nadia [2 ]
Calandrino, Riccardo [1 ]
机构
[1] Ist Sci San Raffaele, Dept Med Phys, I-20132 Milan, Italy
[2] Ist Sci San Raffaele, Dept Radiotherapy, I-20132 Milan, Italy
[3] Ist Sci San Raffaele, Dept Oncol, I-20132 Milan, Italy
关键词
Pancreatic cancer; Unresectable disease; Tomotherapy; Radiotherapy; Toxicity; Dosimetric predictors; INTENSITY-MODULATED RADIOTHERAPY; ACUTE GASTROINTESTINAL TOXICITY; FULL-DOSE GEMCITABINE; PHASE-II; STEREOTACTIC RADIOSURGERY; RADIATION-THERAPY; CANCER; CHEMORADIOTHERAPY; ESCALATION; MANAGEMENT;
D O I
10.1016/j.radonc.2013.05.011
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background and purpose: Hypofractionated radiotherapy (RT) of pancreatic adenocarcinoma is limited by the tolerance of adjacent normal tissues. A better understanding of the influence of dosimetric variables on the rate of toxicity after RT must be considered an important goal. Methods and materials: Sixty-one patients with histologically proven locally advanced disease (LAPD) were analyzed. The therapeutic strategy consisted of induction chemotherapy (ChT) followed by concurrent chemoradiotherapy (CRT). In 39 out of 61 patients the target volume was based on a four-dimensional CT (4D-CT) procedure. Delivered dose was 44.25 Gy in 15 fractions to PTV2, which consisted of pancreatic tumor and regional lymph nodes considered radiologically involved; 23 out of 61 patients received a simultaneous integrated boost (SIB) to a tumor sub-volume infiltrating the great abdominal vessels (PTV1) with dose in the range of 48-58 Gy. RT was delivered with Helical Tomotherapy. Dose-volume histograms (DVHs) of target volumes and organs at risk (OARS) were collected for analysis. The predictive value of clinical/dosimetric parameters was tested by univariate/multivariate analyses. Results: The crude incidence of acute gastrointestinal (GI) grade 2 toxicity was 33%. The 12-month actuarial rate of "anatomical" (gastro-duodenal mucosa damage) toxicity was 13% (95% CI: 4-22%). On univariate analysis, several stomach and duodenum DVH endpoints are predictive of toxicity after moderately hypofractionated radiotherapy. Multivariate analysis confirmed that baseline performance status and the stomach V-20[%] were strong independent predictors of acute GI grade >= 2 toxicity. The high-dose region of duodenum DVH (V-45[%]; V-40[%]) was strongly correlated with grade >= 2 "anatomical" toxicity; the best V-40[%] and V-45[%] cut-off values were 16% and 2.6% respectively. Conclusion: Regarding dosimetric indices, stomach V-20[%] correlates with a higher rate of acute toxicity; more severe acute and late anatomical toxicities are related to the high dose region of duodenum DVH. (C) 2013 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:66 / 71
页数:6
相关论文
共 38 条
  • [1] Intensity-Modulated Radiotherapy for Pancreatic Adenocarcinoma
    Abelson, Jonathan A.
    Murphy, James D.
    Minn, Ann Yuriko
    Chung, Melody
    Fisher, George A.
    Ford, James M.
    Kunz, Pamela
    Norton, Jeffrey A.
    Visser, Brendan C.
    Poultsides, George A.
    Koong, Albert C.
    Chang, Daniel T.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 82 (04): : E595 - E601
  • [2] Intensity-modulated radiotherapy (IMRT) and concurrent capecitabine for pancreatic cancer
    Ben-Josef, E
    Shields, AF
    Vaishampayan, U
    Vaitkevicius, V
    El-Rayes, BF
    McDermott, P
    Burmeister, J
    Bossenberger, T
    Philip, PA
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2004, 59 (02): : 454 - 459
  • [3] A Phase I/II Trial of Intensity Modulated Radiation (IMRT) Dose Escalation With Concurrent Fixed-dose Rate Gemcitabine (FDR-G) in Patients With Unresectable Pancreatic Cancer
    Ben-Josef, Edgar
    Schipper, Mathew
    Francis, Isaac R.
    Hadley, Scott
    Ten-Haken, Randall
    Lawrence, Theodore
    Normolle, Daniel
    Simeone, Diane M.
    Sonnenday, Christopher
    Abrams, Ross
    Leslie, William
    Khan, Gazala
    Zalupski, Mark M.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 84 (05): : 1166 - 1171
  • [4] Internal target volume defined by contrast-enhanced 4D-CT scan in unresectable pancreatic tumour: Evaluation and reproducibility
    Cattaneo, Giovanni Mauro
    Passoni, Paolo
    Sangalli, Giulia
    Slim, Najla
    Longobardi, Barbara
    Mancosu, Pietro
    Bettinardi, Valentino
    Di Muzio, Nadia
    Calandrino, Riccardo
    [J]. RADIOTHERAPY AND ONCOLOGY, 2010, 97 (03) : 525 - 529
  • [5] Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer.: Definitive results of the 2000-01 FFCD/SFRO study
    Chauffert, B.
    Mornex, F.
    Bonnetain, F.
    Rougier, P.
    Mariette, C.
    Bouche, O.
    Bosset, J. F.
    Aparicio, T.
    Mineur, L.
    Azzedine, A.
    Hammel, P.
    Butel, J.
    Stremsdoerfer, N.
    Maingon, P.
    Bedenne, L.
    [J]. ANNALS OF ONCOLOGY, 2008, 19 (09) : 1592 - 1599
  • [6] Future chemoradiation strategies in pancreatic cancer
    Crane, Christopher H.
    Varadhachary, Gauri
    Pisters, Peter W. T.
    Evans, Douglas B.
    Wolff, Robert A.
    [J]. SEMINARS IN ONCOLOGY, 2007, 34 (04) : 335 - 346
  • [7] Gemcitabine-radiotherapy in patients with locally advanced pancreatic cancer
    de Lange, SM
    van Groeningen, CJ
    Meijer, OWM
    Cuesta, MA
    Langendijk, JA
    van Riel, JMGH
    Pinedo, HM
    Peters, GJ
    Meijer, S
    Slotman, BJ
    Giaccone, G
    [J]. EUROPEAN JOURNAL OF CANCER, 2002, 38 (09) : 1212 - 1217
  • [8] A challenge to traditional radiation oncology
    Fowler, JF
    Tomé, WA
    Fenwick, JD
    Mehta, MP
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2004, 60 (04): : 1241 - 1256
  • [9] Gemcitabine with a specific conformal 3D 5FU radiochemotherapy technique is safe and effective in the definitive management of locally eadvanced pancreatic cancer
    Goldstein, D.
    Van Hazel, G.
    Walpole, E.
    Underhill, C.
    Kotasek, D.
    Michael, M.
    Shapiro, J.
    Davies, T.
    Reece, W.
    Harvey, J.
    Spry, N.
    [J]. BRITISH JOURNAL OF CANCER, 2007, 97 (04) : 464 - 471
  • [10] The role of radiotherapy in locally advanced pancreatic carcinoma
    Gutt, Ruchika
    Liauw, Stanley L.
    Weichselbaum, Ralph R.
    [J]. NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2010, 7 (08) : 437 - 447